S1+ Paclitaxel (IV & IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites
Condition: Metastatic Gastric Adenocarcinoma Interventions: Drug: S1; Drug: Paclitaxel; Drug: Bevacizumab; Drug: Oxaliplatin Sponsor: China Medical University, China Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Avastin | Cancer | Cancer & Oncology | China Health | Eloxatin | Gastric (Stomach) Cancer | Gastroenterology | Research